CD274 and neoplasm: A major benefit was also reported in patients with tumor PD-L1 expression of 1% or more (HR 0.52; 95% CI, 0.35 to 0.78), compared to those with a PD-L1 negative tumor (HR 0.73; 95% CI, 0.47 to 1.15).